Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Government Funding Accelerates Venture Interest In China

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - The growth in available government funding for pharmaceutical companies in China is creating a snowball of investment from domestic and multinational pharma companies more willing to overcome intellectual property concerns

You may also be interested in...



Creative Funding Options For China; Investors Battle Perception of Home Court Advantage

The growth in available government funding for pharmaceutical companies in China is creating a snowball of investment from domestic and multinational pharma companies more willing to overcome intellectual property concerns

Creative Funding Options For China; Investors Battle Perception of Home Court Advantage

The growth in available government funding for pharmaceutical companies in China is creating a snowball of investment from domestic and multinational pharma companies more willing to overcome intellectual property concerns

Innovation Sources For Medical Technology Begin Shift To Emerging Markets, But Large Capability Hurdles Remain - PwC Report

TOKYO - The U.S. has been the main source of medical technology innovation for many years, but the growing economies and technological capabilities of countries like China and India could soon shift the balance. The leading emerging markets are already making headway in becoming innovation leaders, although they will need to overcome large caveats that are stunting the development of innovative technologies

Related Content

UsernamePublicRestriction

Register

SC075819

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel